Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Lexicon Pharmaceuticals announced a new post-hoc analysis of pooled Phase 3 data showing that INPEFA® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, significantly reduced the risk of heart failure events in patients with preserved ejection fraction (HFpEF). The analysis, presented at the Heart Failure Association of the European Society of Cardiology Congress, highlighted INPEFA's effectiveness in patients with obesity-related HFpEF. Data from the SOLOIST-WHF and SCORED trials involving 1,932 patients indicated that age, sex, and BMI were important risk factors. Notably, older patients and those with higher BMI saw a greater reduction in primary endpoint events with INPEFA compared to placebo. The findings emphasize the need for personalized treatment strategies for HFpEF patients.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will participate in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will present on May 14, 2024. A webcast will be available on the Lexicon website.
Lexicon Pharmaceuticals reported financial results for the first quarter of 2024, highlighting the progress in the commercial launch of INPEFA for heart failure. They also provided updates on the resubmission of NDA for ZYNQUISTA in Type 1 Diabetes, Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy, and Phase 2b PROGRESS study of LX9211 in Diabetic Peripheral Neuropathic Pain. The company remains focused on advancing its pipeline with the selection of LX9851 for obesity and weight management. Financially, the company reported revenues of $1.1 million, with increased R&D and SG&A expenses resulting in a net loss of $48.4 million for the quarter. Lexicon Pharmaceuticals remains well-capitalized with $355.6 million in cash and investments.
Lexicon Pharmaceuticals, Inc. announced the retirement of Lonnel Coats as CEO and board member effective July 7, 2024. The board is searching for a new CEO. Under Coats' leadership, Lexicon has advanced compounds through development, transformed into a biopharmaceutical business, and built a strong management team. Coats expressed gratitude for the opportunity to lead the company and highlighted upcoming initiatives, including the launch of new products and clinical studies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.